This article is more than 5 years old. Information may no longer be current.

FDA allows phase 1 trial of antisense inhibitor for DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER — The Food and Drug Administration has accepted an investigational new drug application for an antisense inhibitor being developed to treat diabetic macular edema, according to iCo Therapeutics, the drug's developer.

ICo plans to initiate a phase 1 clinical trial of the drug, called iCo-007, in the first half of 2007, a company official said in a press release.

The drug is expected to reduce retinal swelling by decreasing the signaling of vascular endothelial growth factor in the c-raf kinase/MAP kinase pathway, according to the release.